These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12138498)

  • 21. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-throughput protein crystallography and drug discovery.
    Tickle I; Sharff A; Vinkovic M; Yon J; Jhoti H
    Chem Soc Rev; 2004 Oct; 33(8):558-65. PubMed ID: 15480479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics.
    Posner BA
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):487-94. PubMed ID: 16022185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward theragnostics.
    Pene F; Courtine E; Cariou A; Mira JP
    Crit Care Med; 2009 Jan; 37(1 Suppl):S50-8. PubMed ID: 19104225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 7 TM G-protein-coupled receptor target family.
    Jacoby E; Bouhelal R; Gerspacher M; Seuwen K
    ChemMedChem; 2006 Aug; 1(8):761-82. PubMed ID: 16902930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicogenomics in the assessment of immunotoxicity.
    Baken KA; Vandebriel RJ; Pennings JL; Kleinjans JC; van Loveren H
    Methods; 2007 Jan; 41(1):132-41. PubMed ID: 17161310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of emerging technologies in toxicology and safety assessment: regulatory perspectives.
    Leighton JK
    Int J Toxicol; 2005; 24(3):153-5. PubMed ID: 16040567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates.
    Gwathmey JK; Tsaioun K; Hajjar RJ
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):647-60. PubMed ID: 19442031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications of emerging technologies in toxicology and safety assessment.
    Reynolds VL
    Int J Toxicol; 2005; 24(3):135-7. PubMed ID: 16040564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of toxicogenomic data in risk assessment: a regulatory perspective.
    Chan VS; Theilade MD
    Clin Toxicol (Phila); 2005; 43(2):121-6. PubMed ID: 15822767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis of toxicogenomics in the safety assessment of drug candidates.
    Foster WR; Chen SJ; He A; Truong A; Bhaskaran V; Nelson DM; Dambach DM; Lehman-McKeeman LD; Car BD
    Toxicol Pathol; 2007 Aug; 35(5):621-35. PubMed ID: 17654404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative proteomics for drug toxicity.
    Gao Y; Holland RD; Yu LR
    Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approaches for minimizing metabolic activation of new drug candidates in drug discovery.
    Kumar S; Mitra K; Kassahun K; Baillie TA
    Handb Exp Pharmacol; 2010; (196):511-44. PubMed ID: 20020275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database.
    Ganter B; Snyder RD; Halbert DN; Lee MD
    Pharmacogenomics; 2006 Oct; 7(7):1025-44. PubMed ID: 17054413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early chemical development at Legacy Wyeth Research.
    O'Brien MK; Kolb M; Connolly TJ; McWilliams JC; Sutherland K
    Drug Discov Today; 2011 Jan; 16(1-2):81-8. PubMed ID: 21111844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics in diverse ethnic populations--implications for drug discovery and development.
    McCarthy LC; Davies KJ; Campbell DA
    Pharmacogenomics; 2002 Jul; 3(4):493-506. PubMed ID: 12164773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression, dose-response, and phenotypic anchoring: applications for toxicogenomics in risk assessment.
    Daston GP
    Toxicol Sci; 2008 Oct; 105(2):233-4. PubMed ID: 18684776
    [No Abstract]   [Full Text] [Related]  

  • 40. Toxicogenomics in risk assessment: applications and needs.
    Boverhof DR; Zacharewski TR
    Toxicol Sci; 2006 Feb; 89(2):352-60. PubMed ID: 16221963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.